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Abstract 
Background: The aim of this study is to evaluate the anticancer activity of vorinostat‑incorporated nanoparticles 
(vorinostat‑NPs) against HuCC‑T1 human cholangiocarcinoma cells. Vorinostat‑NPs were fabricated by a nanoprecipi‑
tation method using poly(dl‑lactide‑co‑glycolide)/poly(ethylene glycol) copolymer.
Results: Vorinostat‑NPs exhibited spherical shapes with sizes <100 nm. Vorinostat‑NPs have anticancer activity similar 
to that of vorinostat in vitro. Vorinostat‑NPs as well as vorinostat itself increased acetylation of histone‑H3. Further‑
more, vorinostat‑NPs have similar effectiveness in the suppression or expression of histone deacetylase, mutant type 
p53, p21, and PARP/cleaved caspase‑3. However, vorinostat‑NPs showed improved antitumor activity against HuCC‑
T1 cancer cell‑bearing mice compared to vorinostat, whereas empty nanoparticles had no effect on tumor growth. 
Furthermore, vorinostat‑NPs increased the expression of acetylated histone H3 in tumor tissue and suppressed 
histone deacetylase (HDAC) expression in vivo. The improved antitumor activity of vorinostat‑NPs can be explained by 
molecular imaging studies using near‑infrared (NIR) dye‑incorporated nanoparticles, i.e. NIR‑dye‑incorporated nano‑
particles were intensively accumulated in the tumor region rather than normal one.
Conclusions: Our results demonstrate that vorinostat and vorinostat‑NPs exert anticancer activity against HuCC‑T1 
cholangiocarcinoma cells by specific inhibition of HDAC expression. Thus, we suggest that vorinostat‑NPs are a prom‑
ising candidate for anticancer chemotherapy in cholangiocarcinoma.
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chemotherapy, Drug targeting
© 2015 Kwak et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Vorinostat (suberoylanilide hydroxamic acid, SAHA) is 
known to one of histone deacetylase inhibitor (HDACi) 
[1]. In acetylation process, acetyl group in one molecule 
is transferred to another and deacetylation reaction is 
to remove acetyl group from a molecule. HDAC has an 
important role in the transcriptional regulation through 
stabilization of DNA-histone interaction and deacetyla-
tion process is known to have relationship with carcino-
genesis [1]. HDACis such as vorinostat act as a chelator 
for zinc ions in the active site of histone deacetylases 
(HDACs) and vorinostat is regarded as a promising 
cancer chemotherapeutic drug [1]. Vorinostat has been 
approved by the FDA for treatment of cutaneous T cell 
lymphoma [1, 2]. Accumulation of acetylated histones 
and acetylated proteins has correlation with p21WAF1 gene 
expression, apoptotic signals such as mutant-type p53 
and active-type caspase expression, cell differentiation 
and cell death [1–5]. In recent clinical trials, the safety 
and anticancer efficacy vorinostat has been evaluated 
against gastrointestinal (GI) cancer patient [3]. In the 
results of these trials, the report suggested that vorinostat 
can be used as an effective anticancer agent for GI cancer 
[3]. Vorinostat induced both apoptosis and autophagy in 
gastric cancer cell lines and has shown clinical benefits 
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for gastric cancer patients [6, 7]. The anticancer activity 
of vorinostat has also investigated against colon cancer, 
glioma, lung cancer, breast cancer and hepatocellular 
carcinoma in preclinical or clinical trials, both as a single 
treatment or combination with other types of antican-
cer drugs [5–8]. We previously reported that vorinostat 
exhibits anticancer efficacy against HuCC-T1 human 
cholangiocarcinoma (CCA) cells [9]. In this report, we 
show that vorinostat is involved in growth inhibition, 
apoptosis of HuCC-T1 cells in vitro and anti-tumor activ-
ity of HuCC-T1 cell-bearing xenograft model in vivo.
CCA is a malignant tumor that occurs in the epithe-
lium of the biliary tract [10]. Although the rate of inci-
dence of CCA has increased worldwide, the reason for 
its increase remains unclear [11, 12]. Current treatment 
options for CCA include surgical resection, radiotherapy, 
chemotherapy, stent displacement and immunotherapy 
[13–15]. Although surgical resection is believed to be a 
curative treatment option for CCA, patients with CCA 
are frequently diagnosed at an unresectable stage [16]. 
Chemotherapeutic approaches for CCA are considered 
to increase patient survival and quality of life [12]. Vari-
ous chemotherapeutic agents such as gemcitabine, cis-
platin, oxaliplatin, capecitabine and 5-fluorouracil have 
been tested as single agents or in combination in clinical 
trials for CCA [17, 18]. Even though the combination of 
some anticancer agents have been reported to have thera-
peutic advantages, systemic chemotherapy using conven-
tional anticancer agents is still ineffective and shows an 
insignificant increase in survival period. In fact, current 
standard chemotherapeutic treatment for CCA patients 
is normally gemcitabine plus cisplatin [18, 19]. Even 
though combination of these chemotherapeutic agents 
delayed onset of progression, most cases still succumbed 
to CCA and has no significant advances in survivability 
[20]. Because most of chemotherapeutic agents showed 
minimal survival gain and chemotherapeutic agents have 
difficulties in delivery to CCA, targeted therapy for CCA 
patients has been proposed [21]. Novel treatment options 
for a chemotherapeutic approach for CCA are required 
to improve patient survivability.
Nanomedicine such as nanoparticles, liposomes 
and polymeric micelles have advantages in targeting 
malignant solid tumor because they have small sizes of 
<1000  nm and unique structures that can amplify the 
anticancer activity of conventional drugs [22–27]. In 
recent decades, nanomedicine-based drug delivery sys-
tems have also been investigated to target CCA cells 
for diagnosis and chemotherapeutic treatment [22–27]. 
Magnetic nanoparticles were reported to be a useful 
device for the diagnosis of intrahepatic CCA [22, 23]. 
Magnetic drug nanoparticles enveloping chemothera-
peutic drugs were reported to be an effective treatment 
for the inhibition of CCA cell proliferation in a tumor 
xenograft model of nude mice [24]. Totawa et al. reported 
that hybrid liposomes were specifically accumulated in 
human CCA cells and induced cell cycle arrest [25]. In 
our previous study, chitosan nanoparticles incorporating 
all-trans retinoic acid were demonstrated to be effective 
in inhibiting the invasion, migration and proliferation of 
human CCA cells [26]. Stimuli-sensitive nanoparticles 
can also be considered to target CCA cells [27].
In this study, we prepared vorinostat-NPs using biode-
gradable polymers to assess their anticancer effects on 
HuCC-T1 cells in vitro and in vivo. The efficacy of vori-
nostat and vorinostat-NPs in HuCC-T1 cells was studied 
using western blotting, immunohistochemistry and a 




NPs) were fabricated using the nanoprecipitation 
method. Vorinostat and poly(dl-lactide-co-glycolide)/
poly(ethylene glycol) (LGE) block copolymer was dis-
solved in organic solvent. Then this solution was poured 
into aqueous solution and the organic solvent was 
removed. At these procedures, there is no apparent pre-
cipitation of vorinostat in the aqueous phase. To remove 
remained organic solvents and emulsifier (pluronic F68), 
vorinostat-NPs were separated by centrifugation and 
washing process. As shown in Table 1, experimental drug 
loading of vorinostat into the nanoparticles was slightly 
lower than the theoretical value. This might be due to the 
liberation of vorinostat from the nanoparticles during the 
preparation procedure, thereby causing a decrease in the 
effective drug content. Figure 1 shows the characteristics 
of vorinostat-NPs. X-ray powder diffractograms (XRD) 
measurement of lyophilized nanoparticles was employed 
to confirm whether or not free drug was remained in the 
nanoparticle solution as shown in Fig.  1a. As shown in 
Fig. 1a, vorinostat alone has sharp crystalline peaks while 
empty nanoparticles (empty-NPs) have broad peak prop-
erties. Interestingly, vorinostat-NPs also have broad peak 
properties as similar to empty-NPs whereas the physical 
Table 1 Evaluation of drug contents of vorinostat-NPs
Vorinostat contents in the nanoparticles are listed
Polymer/vorinostat 
weight ratio (mg/mg)
Drug contents (%, w/w)
Theoretical Experimen‑
tal
Empty 100/0 – –
Vorinostat‑NP10 100/10 9.1 8.3
Vorinostat‑NP20 100/20 16.7 15.1
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mixture of empty-NPs and vorinostat has both sharp 
and broad crystalline peaks. These results indicated that 
the intrinsic crystallinity of vorinostat was decreased by 
incorporation into the polymer nanoparticles and that 
vorinostat was molecularly distributed in the nanopar-
ticle matrix. Furthermore, these results demonstrated 
that no extensive precipitation of drug has been occurred 
during fabrication procedure and then free drug 
remained was minimized. Additionally, these results also 
indicated that vorinostat was properly payloaded into the 
nanoparticles.
The average particle size was measured to investi-
gate colloidal properties of vorinostat-NPs as shown 
in Fig.  1b. Particles size of nanoparticles was slightly 
increased when vorinostat was incorporated into the 
nanoparticles (Fig. 1b), but the vorinostat content of the 
nanoparticles did not significantly affect the change in 
particle diameter. As shown in Fig.  1c, empty-NPs and 
vorinostat-NPs have spherical shapes under transmission 
electron microscopy (TEM) observation with small parti-
cle sizes of <200 nm. Figure 1d shows the release proper-
ties characteristics of vorinostat from the nanoparticles. 
The initial burst release of the drug was observed for 
1  day and, subsequently, vorinostat-NPs revealed sus-
tained behavior over 5 days. In particular, the release rate 
of vorinostat was slower when the vorinostat content in 
the nanoparticles was higher. These phenomena might be 
due to that hydrophobic drugs in the nanoparticles can 
be aggregated at higher drug content and then aggre-
gated drug released slowly due to the limited solubility 
in the aqueous phase. Gref et al. reported that increased 
drug contents of hydrophobic drugs into core–shell 
type nanospheres lead to aggregation or crystallization 
in the cores of the nanospheres [28]. The crystallization 
Fig. 1 Characteristics of vorinostat‑NPs. a XRD chromatogram; b average particle size; c TEM images; d drug‑release kinetics. Empty‑NPs were 
prepared similar to vorinostat‑incorporated nanoparticles (vorinostat‑NPs) in the absence of vorinostat
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or aggregation of hydrophobic drug in the core of the 
nanospheres led slow rate of dissolution and diffusion of 
drugs into the aqueous phase [28]. Then, the release rate 
of hydrophobic should be slower at higher drug loading 
than lower drug loading.
In vitro anticancer activity of vorinostat‑incorporated 
nanoparticles
Figure 2 shows the anticancer activity of vorinostat and 
vorinostat-NPs against HuCC-T1 cells. For cytotoxic-
ity index, viability of cells was checked in the serum-free 
media as shown in Fig. 2a. The viability of the cells was 
slightly decreased according to the increase of vorinostat 
concentration. In particular, vorinostat-NPs has higher 
cytotoxicity than vorinostat alone even though empty 
nanoparticles have small effect on the viability of cells. In 
growth inhibition study, both vorinostat and vorinostat-
incorporated nanoparticles have low inhibitory effects 
on the growth of HuCC-T1 cells as shown in Fig.  2b. 
These results were compared at vorinostat concentra-
tion of 1 and 5  μg/ml as shown in Fig.  2c. Both vori-
nostat and vorinostat nanoparticles has small inhibitory 
effects on the cell growth at 1 and 5 μg/ml while empty 
nanoparticles did not affect to the growth of HuCC-T1 
cells. Figure 2d shows the apoptosis/necrosis analysis of 
HuCC-T1 cells upon treatment with vorinostat and vori-
nostat-incorporated nanoparticles. As shown in Fig.  2d, 
e, the apoptosis and necrosis of HuCC-T1 cells were 
significantly increased at 5  μg/ml of a vorinostat con-
centration when vorinostat or vorinostat-incorporated 
nanoparticles were treated. The empty nanoparticles 
showed minimal effect to cells.
Figure 3 shows the western blot analysis of molecular 
signals in HuCC-T1 cells upon treatment with vorinostat 
and vorinostat-NPs. As shown in Fig. 3a, acetylated his-
tone H3 was evidently increased upon treatment with 
5 μg/ml vorinostat and vorinostat-NPs, whereas empty-
NPs have no effect on this signal. As shown in Fig.  3b, 
quantitative analysis showed a significant increase in 
ac-histone H3 expression in HuCC-T1 cells, indicating 
that vorinostat-incorporated nanoparticles were effec-
tive in acetylation of Histone H3 as well as vorinostat 
itself. Furthermore, treatment of vorinostat-incorporated 
nanoparticles were also effective in decreasing expression 
of HDAC 1 and HDAC 3 as well as vorinostat itself even 
though HDAC2 expression was almost similar or slightly 
higher than control. In fact, HDAC2 and 3 expression 
of vorinostat-incorporated nanoparticles were slightly 
higher than vorinostat itself at 5  μg/ml concentration 
(Fig. 3a, c). These results might be due to the sustained 
Fig. 2 Anticancer activity of vorinostat and vorinostat‑NP against HuCC‑T1 cells in vitro. 3 × 105 cells for cytotoxicity (a) and 3 × 104 cells for growth 
inhibition (b) test were exposed to vorinostat or vorinostat‑NPs for 24 h, respectively. For cytotoxicity study, serum‑free media were used and grow 
inhibition test was performed with 10 %‑FBS supplemented media. c Comparison of cytotoxicity and growth inhibition of HuCC‑T1 cells follow‑
ing treatment with vorinostat or vorinostat‑NPs at 1and 5 μg/ml. d, e Apoptosis and necrosis analysis of HuCC‑T1 cells. For apoptosis or necrosis, 
1 × 106 cells were exposed to vorinostat or vorinostat‑NPs for 24 h. FITC‑conjugated Annexin V was used to analyze apoptosis and PI was used to 
analyze necrosis
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release properties of nanoparticles, i.e. nanoparticles 
slowly released the drug into the cell culture medium 
and lower concentration of intact vorinostat can affected 
to the cellular expression of HDAC2 and 3. Interestingly, 
empty-NPs affected HDAC expression in cancer cells 
at high concentrations (50  μg/ml). Because the reason 
for these results is not clear, further investigations are 
required in the future. One possible explanation of these 
results is that high concentrations of empty-NPs show 
some cytotoxic effects in the in  vitro cell culture envi-
ronment, even though LGE block copolymer has already 
been approved as a biocompatible polymer and approved 
for human use by the US FDA [29].
Figure  4A shows that the level of mutant p53 was 
significantly decreased both by vorinostat and vori-
nostat-NPs, whereas that of wild-type p53 was not 
significantly changed. The expression of p21 was 
significantly increased upon treatment with both 
vorinostat and vorinostat-NPs. Upon immunocyto-
chemical staining of HuCC-T1 cells, a decrease in 
mutant-type p53 and an increase in p21 were also 
observed. Expression of each protein was normal-
ized to the GAPDH as cytosolic control and lamin B 
as nuclear control. Figure 4B shows apoptosis signals 
in HuCC-T1 cells. As shown in Fig. 4B, a decrease in 
the level of poly-ADP ribose polymerase (PARP) pre-
cursor and an increase in cleaved PARP (at 24  kDa) 
were observed. Furthermore, decreases in caspase-3 
and -9 precursors were also observed upon treatment 
with vorinostat and vorinostat-NPs. And, the level of 
cleaved caspase-3 was increased, as shown in Fig. 4B. 
Including the result of Bax expression, these results 
indicated that vorinostat-NPs induced apoptosis and 
affected the expression of apoptotic molecular sig-
nals to the same extent as did vorinostat. On treat-
ment with vorinostat or vorinostat-NPs, actin was 
disrupted in HuCC-T1 cells as shown in Fig. 4C, indi-
cating that vorinostat-NPs have a similar effect on 
apoptosis and protein changes at the cellular level as 
does vorinostat.
In vivo antitumor activity of vorinostat‑incorporated 
nanoparticles
The increase in tumor volume and changes in body 
weight were monitored. As shown in Fig. 5a, the size of 
the tumor rapidly increased with time following treat-
ment of empty-NPs. However, the volume of the tumor 
was significantly suppressed by treatment of vorinostat 
or vorinostat-NPs. Body weight did not significantly 
change with any of the treatments, indicating that neither 
vorinostat nor nanoparticles were significantly toxic to 
the mice, as shown in Fig.  5b. Interestingly, vorinostat-
NPs showed higher efficacy of tumor growth inhibition: 
tumor volume following treatment of vorinostat-NPs was 
almost 50  % smaller than following treatment of vori-
nostat. Terminal deoxynucleotidyl transferase dUDT 
nick-end-labeling (TUNEL) staining of solid tumors sup-
ported these results, as shown in Fig. 5c: upon treatment 
of vorinostat-NPs, apoptosis was higher than treatment 
of vorinostat, whereas minimal apoptosis was seen upon 
treatment of empty-NPs. Interestingly, the expression of 
ac-histone H3 in tumor tissue was significantly increased 
upon treatment with vorinostat-NPs compared to empty-
NPs and vorinostat as shown in Fig.  6. Furthermore, 
the expression levels of HDAC 1, 2, 3 and 4/5/7 were 
relatively decreased upon treatment of vorinostat and 
vorinostat-NPs, compared to treatment of empty-NPs. 
These results indicated that subcutaneous injection of 
vorinostat-NPs has similar or higher antitumor activity 
compared to vorinostat.
Fig. 3 Western blot analysis of Ac‑histone H3 and HDAC expression 
after treatment with vorinostat or vorinostat‑NPs. a expression of Ac‑
histone H3 and HDACs; b quantitation of Ac‑histone H3 expression; c 
quantitation of HDAC expression
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To clarify the reason for the higher antitumor activity 
of the nanoparticles, near infrared (NIR)-dye-conjugated 
nanoparticles (NIR-NPs) were subcutaneously injected 
into a normal region as well as the site of the tumor, as 
shown in Fig.  7. Intact NIR-dye treated mice showed a 
rapid decrease in both the normal region and the tumor 
site. However, nanoparticle treated mice showed quite 
different results, i.e. nanoparticles remained longer at 
the tumor site than at the normal region. In particular, 
the strongest fluorescence intensity was observed at the 
center of the solid tumor at 1  day after treatment with 
NIR-NPs, whereas intact NIR-dye revealed the strongest 
fluorescence intensity in the region surrounding the solid 
tumor. The treatment of NIR-NPs revealed strong fluo-
rescence intensity after 8 days for injection. These results 
confirmed that vorinostat-NPs have higher antitumor 
activity in vivo than does vorinostat.
Discussion
HDAC expression in cancer cells has a critical role in 
remodeling of chromatin structure, gene expression, cell 
cycle regulation and differentiation [30, 31]. Increased 
HDAC activity is known to result in malignant tumor 
behavior [30]. In particular, Morine et  al. reported that 
Fig. 4 Expression of signals after treatment with vorinostat and vorinostat‑NPs. A a Western blot analysis of apoptotic signal expression in HuCC‑T1 
cells following treatment with vorinostat or vorinostat‑NPs. b–d Immunocytochemistry (×1200) of wild‑type p53, mutant p53 and p21 of HuCC‑
T1 cells after treatment with vorinostat or vorinostat‑NPs. B Western blot analysis of PARP precursor, PARP, caspase‑3 precursor, cleaved caspase‑3, 
caspase‑9 precursor and Bax. C Western blot analysis and immunocytochemistry of actin
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HDAC1 expression in intrahepatic CCA is significantly 
correlated with the stage of carcinogenesis and is related 
to malignant behaviors of cancer, such as angiogen-
esis, lymph node metastasis and vascular invasion [30]. 
They found that the survival rate of the HDAC1-positive 
group was significantly worse than that of the negative 
group. Furthermore, HDAC6 is also known to have a 
strong relationship with the stage of CCA and can thus 
be considered a clinic-pathological parameter for CCA 
[32]. Higher HDAC expression is associated with shorter 
survival times in gastric cancer patients and is regarded 
as an independent prognostic marker for gastric cancer 
[33]. Inhibition of the molecular action of HDAC using 
HDAC inhibitors is a promising candidate for cancer 
chemotherapy [34, 35].
HDAC inhibitors exert anticancer activities on human 
cancer cells through cell cycle arrest, growth arrest, 
activation of apoptotic pathways, autophagic cell death, 
reactive oxygen species (ROS)-mediated cell death and 
mitotic cell death etc. [35, 36]. HDAC inhibitors tightly 
bind to DNA histones and prevent the transcription/
expression of tumor suppressor genes by inducing his-
tone acetylation [35, 36]. Several HDAC inhibitors which 
inhibits class I and II HDACs [36] show minimal intrinsic 
toxicity to human bodies but show dramatic anticancer 
efficacy for cancer [37]. In clinical trials, oral administra-
tion of vorinostat with promising anticancer activity was 
well tolerated in patients with GI cancers [3]. In animal 
tumor xenograft studies, intraperitoneal injection of vori-
nostat induced tumor necrosis and inhibited the growth 
of colon tumors through the inhibition of different sub-
types of HDACs [5].
In our study, we fabricated vorinostat-NPs for treat-
ment of CCA. As shown in Fig.  1, vorinostat-NPs have 
spherical shapes and small diameter <100  nm. They 
showed sustained drug release behavior over 5  days as 
shown in Fig. 1d. Especially, nanoparticles having higher 
vorinostat contents (vorinostat-NP20) showed slower 
Fig. 5 Antitumor activity of vorinostat or vorinostat‑NP in HuCC‑T1 tumor xenograft mice model. (dose 50 mg vorinostat/kg) a tumor volume; b 
body weight; c TUNEL assay (×400) of extracted tumor tissues. HuCC‑T1 human CCA cells (1 × 107) were implanted into the back of BALb/C nude 
mouse. 2 weeks later, vorinostat, empty‑NPs or vorinostat‑NPs were injected subcutaneously beside the solid tumor and the day of drug injection 
was set as day 0. Tumor volume was calculated using the formula V = (a × [b]2)/2, with a being the largest and b being the smallest diameter. For 
TUNNEL assay, tumors were isolated and fixed with 4 % formamide after 30 days of injection
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release kinetic. These results might be due to that hydro-
phobic drug can be aggregated at higher drug loading 
contents and release of aggregated drug can be delayed 
compared to the nanoparticles with lower drug contents 
(vorinostat-NP10). These phenomena were frequently 
reported by several investigators. To assess biological 
activity, vorinostat-NPs were treated to HuCC-T1 cells 
and their anticancer activity was compared to vorinostat 
itself at in  vitro and in  vivo. Vorinostat-NPs as well as 
vorinostat properly inhibited the growth of HuCC-T1 
cells in  vitro and the growth of tumor volume in  vivo 
through inhibition of HDAC expression in the HuCC-
T1 cells and tumor tissues, as shown in Figs. 3, 5 and 6. 
Furthermore, vorinostat-NPs have higher antitumor 
activity compared to vorinostat, due to the sustained 
release properties of nanoparticles. The apoptotic signals 
of HuCC-T1 cells were also significantly altered upon 
treatment with vorinostat or vorinostat-NPs in vitro and 
in vivo as shown in Figs. 3, 4 and 5. As shown in Fig. 4, 
levels of mutant p53 were significantly decreased with lit-
tle change in wild-type p53 and this suppression is cor-
related with the expression of PARP/cleaved caspase-3. 
Other researchers have reported that the expression of 
mutant p53 was significantly decreased in a dose- and 
time-dependent manner [38, 39]. For example, Yan et al. 
found that disruption of HDAC8 expression significantly 
inhibits proliferation of cancer cells having mutant-type 
p53 irrespective of wild-type p53. In their results, col-
ony formation of mutant-type p53 cell lines SW480 was 
remarkably decreased by treatment of vorinostat while 
wild-type p53 cell lines HCT116 showed little changes 
[40]. Furthermore, both vorinostat-NPs and vorinostat 
were able to arrest cell growth and induced apoptosis as 
shown in Figs. 3 and 4. And, they increased the expres-
sion of p21, a cyclin-dependent kinase inhibitor I, in a 
dose-dependent manner and this is correlated with other 
apoptosis signals. Thenaa et  al. also reported that vori-
nostat inhibits mammary cell growth through altered p21 
expression and cell cycle arrest [41]. Our results showed 
that vorinostat-incorporated nanoparticles as well as 
vorinostat itself also affects in induction of apoptotic sig-
nals, suppression of mutant-type p53, up-regulation of 
p21 and disruption of actin in HuCC-T1 cells. Further-
more, vorinostat-incorporated nanoparticles were also 
higher efficacy than vorinostat itself at in  vivo animal 
Fig. 6 Immunohistochemistry (×400) of tumor tissues from HuCC‑T1 
cell bearing xenograft mouse model. To study HDAC expression, 
tumor tissues were stained with acetyl histone H3, HDAC1, HDAC2, 
HDAC3, and HDAC4/5/7 antibodies
Fig. 7 In vivo fluorescence imaging of HuCC‑T1 tumor xenograft 
mice model. NIR dye‑incorporated NPs were simultaneously injected 
into a normal region and beside the tumor region of the back of 
mouse. Mouse were observed with the Maestro 2™ In Vivo imaging 
system at 780 nm
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tumor xenograft study. Treatment with vorinostat or 
vorinostat-incorporated nanoparticles increased acetyla-
tion of histone H3 (Ac-Histone H3) and then decreased 
HDAC expression as shown in Fig. 6. Di Gennaro et al. 
also reported that subcutaneous injection of vorinostat 
at a dose of 100 mg/kg against SW620 colorectal cancer 
xenografts increases Ac-Histone H3 and showed syner-
gized effect with capecitabine in the inhibition of tumor 
growth [42]. Furthermore, intravenous injection of vori-
nostat or vorinostat-incorporated nanoparticles is known 
to sensitize radiotherapy and then effectively inhibit 
growth of PC3 tumor xenograft in mice [43].
Hydrogels or nanocarriers are known to improve anti-
tumor activity of vorinostat in vivo animal tumor xeno-
graft model [44–46]. Vorinostat-NPs caused antitumor 
activity, apoptotic expression in TUNEL assay and inhibi-
tory activity of HDAC expression compared with vori-
nostat itself, as shown in Figs. 5 and 6. Antitumor activity 
of drugs can be improved at in vivo circumstances by use 
of biodegradable polymers for controlled drug release 
[41]. Therefore, these results can be explained by the 
sustained release properties of vorinostat-NPs. Li et  al. 
reported that biodegradable thermosensitive hydro-
gel enhances the therapeutic efficacy of vorinostat and 
significantly inhibited intratumoral angiogenesis [44]. 
Furthermore, Mohamed et  al. reported that polymeric 
micelles significantly enhance half-lives in blood and bio-
availability of vorinostat in rats by intravenous injection 
and oral administration [45]. Nanocarriers also increase 
the half-life of vorinostat in blood and improve the anti-
tumor activity of vorinostat [46]. Gref et  al. reported 
potential of long blood circulation of core–shell type 
nanospheres composed of PLGA-PEG block copolymer 
rather than plain nanoparticles [28]. Systemic approach 
of chemotherapeutic agents is known to have limited 
clinical benefit due to the difficulties of drug delivery to 
CCA tumor [20, 21, 47]. For this reason, alternative treat-
ment regimen is required to deliver the anticancer drugs 
to CCA tumor. Therefore, we focused on the possibility 
of drug delivery to CCA tumor by local administration 
of vorinostat-incorporated nanoparticles. Practically, 
growth of tumors originated in HuCC-T1 cells in the 
back of the mice was effectively suppressed compared 
to vorinostat itself and empty nanoparticle treatment as 
shown in Fig.  5. To clarify vorinostat delivery to tumor 
tissues, NIR-dye was physically incorporated into the 
nanoparticles as similar to vorinostat and injected beside 
tumor tissues. As shown in Fig. 7, it is likely that nano-
particles were efficiently delivered to tumor tissues com-
pared to free NIR-dye. Furthermore, NIR-NPs stayed 
longer in the tumor tissue than free NIR-dye. Practi-
cally, NIR-NPs were rapidly cleared from normal region 
but not in tumor region while free NIR-dye was rapidly 
cleared both in normal and tumor region. The reason of 
improved antitumor activity of vorinostat nanoparticles 
compared to vorinostat itself can be explained by these 
results. Other researcher also reported that nanoparticles 
can be stayed longer in the injection site and efficiently 
delivered to tumor tissues compared to free NIR-dye 
[48]. In other words, enhanced permeation and reten-
tion effect of macromolecules and nanomedicines in the 
tumor tissues also can be considered to explain these 
results [49, 50]. In our results, vorinostat-NPs showed 
higher anticancer activity than intact vorinostat and have 
higher efficacy in the drug delivery to tumor tissue. We 
suggest that vorinostat nanoparticles are promising can-
didate to treat CCA.
Conclusion
We prepared vorinostat-NPs using biodegradable 
block copolymer for anticancer therapy in HuCC-T1 
CCA cells. Vorinostat-NPs have similar anticancer 
activities in terms of growth inhibition, apoptosis and 
inhibition of HDAC expression in vitro to that of vori-
nostat alone. However, vorinostat-NPs show improved 
antitumor activity in xenograft mice model and a 
higher inhibition rate of HDAC expression in  vivo. 
The higher anticancer activity of vorinostat-NPs can 
be explained by NIR-NPs, i.e. NIR-NPs were remained 
in the tumor tissue longer than did free NIR dye. We 
suggest that vorinostat nanoparticles can be used as a 




Vorinostat was purchased from LC Labs. Co. (Woburn, 
MA, USA). LGE copolymer (Resomer® RGP d 50105) was 
purchased from Boehringer Ingelheim Pharma GmbH & 
Co. (Ingelheim am Rhein, Germany). Pluronic F68, dime-
thyl sulfoxide (DMSO) and acetone were purchased from 
Sigma-Aldrich Chem. Co. (St. Louis, MO, USA). Dialysis 
membranes with molecular weight cutoffs of 8000 g/mol 
were purchased from Spectra/PorTM (Spectrum Labo-
ratories Inc, Rancho Dominguez, CA, USA). RPMI1640 
media, fetal bovine serum (FBS) and all cell culture com-
ponents were purchased from Life Technologies (Grand 
Island, NY, USA). All reagents and organic solvents used 
were of extra-pure grade.
Fabrication of vorinostat‑incorporated nanoparticles
One hundred milligrams of LGE were dissolved in 10 ml 
acetone. Ten and twenty mg of vorinostat was dissolved 
in 0.2 and 0.4  ml of DMSO, respectively. Then, vori-
nostat solution was mixed with LGE/acetone solution. 
The mixed solution was dropped in 20  ml of deionized 
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water [Pluronic F68, 0.1  % (w/v)] for 10  min and then 
the organic solvent was evaporated under vacuum. The 
nanoparticle solution was recovered by ultra-centrifu-
gation at 100,000×g (Supra 30  K, Vacuum High Speed 
Centrifuge, Hanil Science Industrial Co. Ltd., Incheon, 
Korea). Subsequently, harvested nanoparticles were 
washed with 10 ml of deionized water and then harvested 
again by ultra-centrifugation. The washing procedure 
was repeated three times. The resulting nanoparticles 
were reconstituted in deionized water or lyophilized. To 
measure vorinostat content in the nanoparticles, 5 mg of 
lyophilized nanoparticles were dissolved in DMSO. The 
drug content and loading efficiency of vorinostat in the 
vorinostat-NPs was evaluated using the Flexar high-per-
formance liquid chromatography (HPLC) system (Per-
kin-Elmer Life and Analytical Sciences, Waltham, MA, 
USA).
Drug concentrations were determined using the HPLC 
system as follows: the Flexar HPLC system was equipped 
with a Solvent Manager 5-CH degasser, an autosampler, 
a quaternary LC pump, a column oven and an UV/VIS 
detector. Chromatography was performed on a guard 
column (SecurityGuard® Guard Cartridge Kit; Phenom-
enex, Torrance, CA, USA) and a C18 column (Brownlee 
C18®, 5 micrometer, 150 ×  4.6; Perkin Elmer) at 37  °C. 
Vorinostat was eluted isocratically with mobile phase 
(acetonitrile/0.1  % formic acid at a ratio of 22/78) at a 
flow rate of 1  ml/min and monitored at 241  nm. Chro-
matograms were recorded and integrated with the 
Chromera 2.1 system software (Perkin Elmer Life and 
Analytical Sciences, Waltham, MA, USA).
Characterization of vorinostat‑incorporated nanoparticles
The morphology of the nanoparticles was observed 
using TEM (JEM-2000 FX II microscope, JEOL, Tokyo, 
Japan). The nanoparticle solution was dropped onto a 
carbon film coated on a copper grid and then the nano-
particles were negatively stained with phosphotungstic 
acid (0.05  % w/w). TEM observation was performed at 
an accelerating voltage of 80 kV. Particle size was meas-
ured using the Nano-ZS apparatus (Malvern Instru-
ments, Malvern, UK). Nanoparticles were reconstituted 
in deionized water (nanoparticle concentration 0.1  mg/
ml) and then used to determine particle size. The crys-
tallinity of vorinostat and vorinostat-NPs were ana-
lyzed using XRD (Rigaku D/Max-1200, Rigaku, Tokyo, 
Japan) equipped with Ni-filtered Cu Ka radiation (40 kV, 
Drug content = [(Drug weight in the nanoparticles)/
(weight of nanoparticles)] × 100
Loading efficiency = [(Residual drug in the nanoparticle)/
(initial feeding amount of drug)] × 100
20 mA). The vorinostat powder and lyophilized nanopar-
ticle solid were used to measure crystallinity using XRD.
Drug release study
Drug release testing was performed using phosphate-
buffered saline (PBS; 10 mM, pH 7.4) solution at 37  °C. 
Five milligrams of nanoparticles in 1  ml of deionized 
water were added to 4  ml of PBS and this solution was 
then introduced into a dialysis tube. This dialysis tube 
was immersed in a 100  ml bottle with 95  ml of PBS. 
Whole media were taken at predetermined time intervals 
and exchanged with fresh PBS. The concentration of the 
released drug was measured using the HPLC system. The 
percentage of released drug was calculated from follow-
ing equation: [(amount of released drug/total weight of 
drug in the nanoparticles) × 100].
Cell culture
HuCC-T1 cell line was obtained from the Health Science 
Research Resources Bank (Osaka, Japan) and maintained 
with RPMI1640 medium supplemented with 10 % heat-
inactivated FBS and 1 % penicillin/streptomycin at 37 °C 
in a humidified atmosphere containing 5 % CO2.
Cell cytotoxicity and growth inhibition study
HuCC-T1 cells were seeded in 24-well plates at a density of 
3 × 104 and 3 × 105 cells per well for the growth inhibition 
and cytotoxicity assays, respectively. Following this, each 
plate was incubated overnight in a CO2 incubator. Vori-
nostat in DMSO and vorinostat-NPs were diluted with 
RPMI1640 medium containing 10  % FBS for the growth 
inhibition assay at various concentrations and then added 
to HuCC-T1 cells in 24-well plates following 24 h incuba-
tion. The cytotoxicity assay was carried out using serum-
free RPMI1640 media. The control was treated with 0.1 % 
(v/v) DMSO. Cells were trypsinized, harvested and resus-
pended in PBS. Trypan blue was added and the number 
of cells was counted using the Countess™ Automated Cell 
Counter (Invitrogen, Carlsbad, CA, USA). The reduction 
of viable cells by treatment of vorinostat or vorinostat-
incorporated nanoparticles compared to control treatment 
was calculated and expressed as mean ± SD.
Apoptosis and necrosis analysis
HuCC-T1 cells were seeded in 6-well plates at a density 
of 1 × 106 cells per well and exposed to various concen-
trations of vorinostat and vorinostat-NPs for 24  h. The 
cells were harvested, washed with PBS, resuspended in 
500 μl binding buffer and stained with FITC-conjugated 
Annexin V for apoptosis analysis and with PI for necro-
sis analysis. These cells were analyzed by flow cytometry 
(BD biosciences, San Jose, CA, USA).
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Western blot analysis and immunocytochemistry
HuCC-T1 cells were seeded in 6-well plates at a density 
of 1 × 106 cells per well and exposed to various concen-
trations of vorinostat and vorinostat-NPs for 24 h. Cells 
were trypsinized and washed with cold PBS. The cells 
were collected by centrifugation and lysed in lysis buffer 
containing protease inhibitors [50  mM Tris, 150  mM 
NaCl, 1 % NP-40, 0.5 % deoxycholic acid, 0.1 % sodium 
dodecyl sulfate (SDS)] with phenylmethylsulfonyl fluo-
ride and a protease inhibitor cocktail (Roche Diagnostics, 
Basel, Switzerland). The cell suspension was cleared by 
centrifugation at 14,000×g for 30  min at 4  °C and then 
supernatant or cell lysates were collected. The protein 
concentration was determined using the BCA Protein 
Assay kit (Pierce, Rockford, IL, USA).
For western blotting, 50 μg protein was subjected to SDS-
polyacrylamide gel electrophoresis (SDS-PAGE), trans-
ferred to a polyvinyl difluoride membrane, blocked with 
5 % skim milk in TBS-T and probed with an appropriate 
primary antibody followed by a secondary HRP-conjugated 
antibody. Proteins were detected by chemiluminescence. 
Proteins were quantified by digital analyses.
Antitumor activity of vorinostat‑incorporated 
nanoparticles against the animal tumor xenograft model
To assess the antitumor activity of vorinostat-NPs, a 
tumor xenograft model was prepared by subcutane-
ous injection of HuCC-T1 cells into the backs of nude 
mice. HuCC-T1 cells (1  ×  107 cells) in a total volume 
of 100  μl were subcutaneously injected into the backs 
of male nude mice (5-week-old and 20–25 g in weight; 
Orient, Seongnam, South Korea). When the solid tumor 
reached approximately 4–5  mm in diameter, empty-
NPs, vorinostat and vorinostat-NPs were injected sub-
cutaneously adjacent to the solid tumor. Treatment dose 
was adjusted to 1  mg vorinostat (50  mg/kg). A total 
of 18 mice were divided into three groups, as follows: 
(1) vorinostat-injected, (2) empty-NPs injected and (3) 
vorinostat-NP injected. Body weight and tumor volume 
were measured twice a week, starting on the first day of 
treatment. Two perpendicular diameters of the tumor 
were measured and tumor volume was calculated using 
the formula V =  (a ×  [b]2)/2, with a being the largest 
and b being the smallest diameter. The animal study 
was carried out according to the guidelines of the Ani-
mal Treatment and Research Council of Pusan National 
University.
Immunohistochemistry
After 30 days of injection, tumors were isolated and fixed 
in 4 % formamide, paraffin-embedded and sliced for hema-
toxylin and eosin (H&E) staining or for the TUNEL assay. 
For immunohistochemical staining of the tumors, acetyl 
histone H3 antibody was diluted to 1:500 and HDAC1 
antibody was dilued to 1:100. HDAC2, HDAC3, and 
HDAC4/5/7 antibodies were diluted to 1:200. Staining was 
performed using an Envision kit (Life Technologies, Carls-
bad, CA, USA) according to the manufacturer’s protocol.
Fluorescence imaging of solid tumor‑bearing mice
To study biodistribution of vorinostat-NPs, hydropho-
bic NIR-dye (XenoLight DiR, Caliper Lifesciences, MA 
01748-1668, USA) was incorporated into the nanopar-
ticles. Four milligrams of hydrophobic NIR-dye was dis-
solved in 0.2  ml of DMSO and mixed with 100  mg of 
LGE dissolved in acetone. This solution was dropped in 
20 ml of deionized water [Pluronic F68, 0.1 % (w/v)] for 
10  min and then organic solvent was evaporated under 
vacuum. After that, hydrophobic NIR-NPs were har-
vested by same procedure as described above. To meas-
ure content of hydrophobic NIR-dye in the nanoparticles, 
hydrophobic NIR-NPs were dissolved in 10 ml of DMSO 
and the concentration was measured with fluorescence 
spectrophotometer (RF-5301 fluorescence spectrofluo-
rophotometer, Shimadzu, Tokyo, Japan). The content of 
hydrophobic near-infrared was calculated to 3.6 % (w/w).
For tumor imaging, NIR-NPs (50 mg/kg) were injected 
subcutaneously beside tumor tissue. To compare uptake 
of nanoparticles at tumor tissue and normal tissue, same 
quantity of NIR-NPs was also injected subcutaneously in 
the normal region. Mouse was observed using the Maes-
tro 2™ In Vivo imaging system (Cambridge Research and 
Instruments, Inc., Woburn, MA 01801, USA) at 780 nm.
Quantification of image intensity
Quantification of staining intensities was calculated using 
the ImageJ (ver 1.42q) software (NIH, Bethesda, MD, USA).
Statistical analysis
Statistical analyses of the data from treated and untreated 
cells were performed using the Student’s t test. A p value 
<0.05 was considered to be statistically significant.
Abbreviations
vorinostat‑NPs: vorinostat‑incorporated nanoparticles; HDAC: histone dea‑
cetylase; HDACi: histone deacetylase inhibitor; GI: gastrointestinal; CCA: chol‑
angiocarcinoma; LGE: poly(dl‑lactide‑co‑glycolide)‑b‑poly(ethylene glycol); 
DMSO: dimethyl sulfoxide; FBS: fetal bovine serum; TEM: transmission electron 
microscopy; XRD: X‑ray powder diffractograms; PARP: poly‑ADP ribose poly‑
merase; SDS: sodium dodecyl sulfate; PAGE: polyacrylamide gel electrophore‑
sis; TUNEL: terminal deoxynucleotidyl transferase dUDP nick‑end‑labeling; NIR: 
near‑infrared; NIR‑NPs: NIR‑dye conjugated nanoparticles; empty‑NPs: empty 
nanoparticles.
Authors’ contributions
TWK carried out fabrication of vorinostat‑loaded nanoparticles and cell culture 
study. DHK carried out animal study using mouse tumor xenograft model. 
YIJ conceived of this research and participated in its design. DHK drafted a 
manuscript and organized all the procedures. All authors read and approved 
the final manuscript.
Page 12 of 13Kwak et al. J Nanobiotechnol  (2015) 13:60 
Author details
1 Biomedical Research Institute, Pusan National University Hospital, 179 
Gudeok‑ro, Seo‑gu, Busan 602‑739, Republic of Korea. 2 School of Medicine, 
Pusan National University, Yangsan, Gyeongnam 626‑770, Republic of Korea. 
3 Department of Internal Medicine, Pusan National University Yangsan Hospi‑
tal, Yangsan, Gyeongnam 626‑770, Republic of Korea. 
Acknowledgements
This study was supported by a grant of the Korean Health Technology 
R&D Project, Ministry of Health and Welfare, Republic of Korea (Project No. 
HI14C2220).
Compliance with ethical guidelines
Competing interests
The authors declare that they have no competing interests.
Received: 6 April 2015   Accepted: 10 September 2015
References
 1. Richon VM. Cancer biology: mechanism of antitumour action of vori‑
nostat (suberoylanilidehydroxamic acid), a novel histone deacetylase 
inhibitor. Br J Cancer. 2006;95:S2–6.
 2. Takada Y, Gillenwater A, Ichikawa H, Aggarwal BB. Suberoylanilidehy‑
droxamic acid potentiates apoptosis, inhibits invasion, and abolishes 
osteoclastogenesis by suppressing nuclear factor‑kappaB activation. J 
Biol Chem. 2006;281:5612–22.
 3. Doi T, Hamaguchi T, Shirao K, Chin K, Hatake K, Noguchi K, et al. Evalu‑
ation of safety, pharmacokinetics, and efficacy of vorinostat, a histone 
deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a 
phase I clinical trial. Int J Clin Oncol. 2013;18:87–95.
 4. Claerhout S, Lim JY, Choi W, Park YY, Kim K, Kim SB, et al. Gene expression 
signature analysis identifies vorinostat as a candidate therapy for gastric 
cancer. PLoS One. 2011;6:e24662.
 5. Jin JS, Tsao TY, Sun PC, Yu CP, Tzao C. SAHA inhibits the growth of colon 
tumors by decreasing histone deacetylase and the expression of cyclin 
D1 and survivin. Pathol Oncol Res. 2012;18:713–20.
 6. Chinnaiyan P, Chowdhary S, Potthast L, Prabhu A, Tsai YY, Sarcar B, et al. 
Phase I trial of vorinostat combined with bevacizumab and CPT‑11 in 
recurrent glioblastoma. Neuro Oncol. 2012;14:93–100.
 7. Ramaswamy B, Fiskus W, Cohen B, Pellegrino C, Hershman DL, Chuang 
E, et al. Phase I–II study of vorinostat plus paclitaxel and bevacizumab 
in metastatic breast cancer: evidence for vorinostat‑induced tubu‑
lin acetylation and Hsp90 inhibition in vivo. Breast Cancer Res Treat. 
2012;132:1063–72.
 8. Liu YL, Yang PM, Shun CT, Wu MS, Weng JR, Chen CC. Autophagy potenti‑
ates the anti‑cancer effects of the histone deacetylase inhibitors in 
hepatocellular carcinoma. Autophagy. 2010;6:1057–65.
 9. Kwak TW, Kim do H, Chung CW, Lee HM, Kim CH, Jeong YI, et al. Synergis‑
tic anticancer effects of vorinostat and epigallocatechin‑3‑gallate against 
HuCC‑T1 human cholangiocarcinoma cells. Evid Based Complement 
Altern Med. 2013;2013:185158.
 10. Lim JH. Cholangiocarcinoma: morphologic classification according to 
growth pattern and imaging findings. Am J Roentgenol. 2003;181:819–27.
 11. Khan SA, Taylor‑Robinson SD, Toledano MB, Beck A, Elliott P, Thomas 
HC. Changing international trends in mortality rates for liver, biliary and 
pancreatic tumours. J Hepatol. 2002;37:806–13.
 12. Sirica AE. Cholangiocarcinoma: molecular targeting strategies for chemo‑
prevention and therapy. Hepatology. 2005;41:5–15.
 13. Ciombor KK, Goff LW. Advances in the management of biliary tract can‑
cers. Clin Adv Hematol Oncol. 2013;11:28–34.
 14. Brunner TB, Eccles CL. Radiotherapy and chemotherapy as therapeutic 
strategies in extrahepatic biliary duct carcinoma. Strahlenther Onkol. 
2010;186:672–80.
 15. Skipworth JR, Olde Damink SW, Imber C, Bridgewater J, Pereira SP, Malagó 
M. Surgical, neo‑adjuvant and adjuvant management strategies in biliary 
tract cancer. Aliment Pharmacol Ther. 2011;34:1063–78.
 16. Rizvi S, Gores GJ. Pathogenesis, diagnosis and management of cholangio‑
carcinoma. Gastroenterology. 2013;145:1215–29.
 17. Cereda S, Passoni P, Reni M, Viganò MG, Aldrighetti L, Nicoletti R, et al. 
The cisplatin, epirubicin, 5‑fluorouracil, gemcitabine (PEFG) regimen in 
advanced biliary tract adenocarcinoma. Cancer. 2010;116:2208–14.
 18. Kim ST, Park JO, Lee J, Lee KT, Lee JK, Choi SH, et al. A phase II study 
of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer. 
2006;106:1339–46.
 19. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas 
A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract 
cancer. N Engl J Med. 2010;362:1273–81.
 20. Leong E, Chen WW, Ng E, Van Hazel G, Mitchell A, Spry N. Outcomes from 
combined chemoradiotherapy in unresectable and locally advanced 
resected cholangiocarcinoma. J Gastrointest Cancer. 2012;43:50–5.
 21. Furuse J, Okusaka T. Targeted therapy for biliary tract cancer. Cancers 
(Basel). 2011;3:2243–54.
 22. Braga HJ, Imam K, Bluemke DA. MR imaging of intrahepatic cholangio‑
carcinoma: use of ferumoxides for lesion localization and extension. Am J 
Roentgenol. 2011;177:111–4.
 23. Lee Y, Lee JS, Kim CM, Jeong JY, Choi JI, Kim MJ. Area of paradoxical signal 
drop after the administration of superparamagnetic iron oxide on the 
T2‑weighted image of a patient with lymphangitic metastasis of the liver. 
Magn Reson Imaging. 2008;26:577–82.
 24. Tang T, Zheng JW, Chen B, Li H, Li X, Xue KY, et al. Effects of targeting 
magnetic drug nanoparticles on human cholangiocarcinoma xenografts 
in nude mice. Hepatobiliary Pancreat Dis Int. 2007;6:303–7.
 25. Towata T, Komizu Y, Kariya R, Suzu S, Matsumoto Y, Kobayashi N, et al. 
Hybrid liposomes inhibit the growth of cholangiocarcinoma by induction 
of cell cycle arrest in G1 phase. Bioorg Med Chem Lett. 2010;20:3680–2.
 26. Chung KD, Jeong YI, Chung CW, Kim do H, Kang DH. Anti‑tumor 
activity of all‑trans retinoic acid‑incorporated glycol chitosan nanopar‑
ticles against HuCC‑T1 human cholangiocarcinoma cells. Int J Pharm. 
2012;422:454–61.
 27. Hwang JH, Choi CW, Kim do HW, Kim H, Kwak TW, Lee HM, et al. Dextran‑
b‑poly(l‑histidine) copolymer nanoparticles for pH‑responsive drug 
delivery to tumor cells. Int J Nanomedicine. 2013;8:3197–207.
 28. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer 
R. Biodegradable long‑circulating polymeric nanospheres. Science. 
1994;263:1600–3.
 29. Oh JK. Polylactide (PLA)‑based amphiphilic block copolymers: synthesis, 
self‑assembly and biomedical applications. Soft Matter. 2011;7:5096–108.
 30. Morine Y, Shimada M, Iwahashi S, Utsunomiya T, Imura S, Ikemoto T, et al. 
Role of histone deacetylase expression in intrahepatic cholangiocarci‑
noma. Surgery. 2012;151:412–9.
 31. Sun WJ, Zhou X, Zheng JH, Lu MD, Nie JY, Yang XJ, et al. Histone acetyl‑
transferases and deacetylases: molecular and clinical implications to 
gastrointestinal carcinogenesis. Acta Biochim Biophys Sin (Shanghai). 
2012;44:80–91.
 32. Boonjaraspinyo S, Boonmars T, Kaewkes S, Laummaunwai P, Pinlaor 
S, Loilome W, et al. Down‑regulated expression of HSP70 in correla‑
tion with clinicopathology of cholangiocarcinoma. Pathol Oncol Res. 
2012;18:227–37.
 33. Weichert W, Röske A, Gekeler V, Beckers T, Ebert MP, Pross M, et al. Associa‑
tion of patterns of class I histone deacetylase expression with patient 
prognosis in gastric cancer: a retrospective analysis. Lancet Oncol. 
2008;9:139–48.
 34. Weichert W. HDAC expression and clinical prognosis in human malignan‑
cies. Cancer Lett. 2009;280:168–76.
 35. Fang JY. Histone deacetylase inhibitors, anticancerous mechanism 
and therapy for gastrointestinal cancers. J Gastroenterol Hepatol. 
2005;20:988–94.
 36. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular 
mechanisms of action. Oncogene. 2007;26:5541–52.
 37. Vigushin DM, Coombes RC. Histone deacetylase inhibitors in cancer 
treatment. Anticancer Drugs. 2012;13:1–13.
 38. Yan W, Liu S, Xu E, Zhang J, Zhang Y, Chen X, et al. Histone deacetylase 
inhibitors suppress mutant p53 transcription via histone deacetylase 8. 
Oncogene. 2013;32:599–609.
 39. Li D, Marchenko ND, Moll UM. SAHA shows preferential cytotoxicity in 
mutant p53 cancer cells by destabilizing mutant p53 through inhibition 
of the HDAC6‑Hsp90 chaperone axis. Cell Death Differ. 2011;18:1904–13.
Page 13 of 13Kwak et al. J Nanobiotechnol  (2015) 13:60 
 40. Chen YX, Fang JY, Zhu HY, Lu R, Cheng ZH, Qiu DK. Histone acetylation 
regulates p21WAF1 expression in human colon cancer cell lines. World J 
Gastroenterol. 2004;10:2643–6.
 41. Said TK, Moraes RCB, Sinha R, Medina D. Mechanisms of suberoylanilide 
hydroxamic acid inhibition of mammary cell growth. Breast Cancer Res. 
2001;3:122–33.
 42. Di Gennaro E, Piro G, Chianese MI, Franco R, Di Cintio A, Moccia T, Luciano 
A, de Ruggiero I, Bruzzese F, Avallone A, Arra C, Budillon A. Vorinostat 
synergises with capecitabine through upregulation of thymidine phos‑
phorylase. Br J Cancer. 2010;103:1680–91.
 43. Wang EC, Min Y, Palm RC, Fiordalisi JJ, Wagner KT, Hyder N, Cox AD, Caster 
JM, Tian X, Wang AZ. Nanoparticle formulations of histone deacetylase 
inhibitors for effective chemoradiotherapy in solid tumors. Biomaterials. 
2015;51:208–15.
 44. Li J, Gong C, Feng X, Zhou X, Xu X, Xie L, et al. Biodegradable thermosen‑
sitive hydrogel for SAHA and DDP delivery: therapeutic effects on oral 
squamous cell carcinoma xenografts. PLoS One. 2012;7:e33860.
 45. Mohamed EA, Zhao Y, Meshali MM, Remsberg CM, Borg TM, Foda 
AM, et al. Vorinostat with sustained exposure and high solubility in 
poly(ethylene glycol)‑b‑poly(dl‑lactic acid) micelle nanocarriers: char‑
acterization and effects on pharmacokinetics in rat serum and urine. J 
Pharm Sci. 2012;101:3787–98.
 46. Kim JY, Shim G, Choi HW, Park J, Chung SW, Kim S, et al. Tumor vasculature 
targeting following co‑delivery of heparin‑taurocholate conjugate and 
suberoylanilide hydroxamic acid using cationic nanolipoplex. Biomateri‑
als. 2012;33:4424–30.
 47. Thomas MB. Systemic and targeted therapy for biliary tract tumors and 
primary liver tumors. Surg Oncol Clin N Am. 2014;23:369–81.
 48. Park W, Park SJ, Na K. The controlled photoactivity of nanoparticles 
derived from ionic interactions between a water soluble polymeric pho‑
tosensitizer and polysaccharide quencher. Biomaterials. 2011;32:8261–70.
 49. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability 
and the EPR effect in macromolecular therapeutics: a review. J Control 
Release. 2000;65:271–84.
 50. Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced perme‑
ability and retention effect for tumor targeting. Drug Discov Today. 
2006;11:812–8.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
